Ordering Recommendation

Surveillance and monitoring of hepatocellular carcinoma; test is less specific than one which includes AFP-L3 isoform.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation

Plain Red or Serum Separator Tube (SST)        .

Specimen Preparation

Allow specimen to clot completely at room temperature. Separate from cells within 4 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.2 mL)

Storage/Transport Temperature


Unacceptable Conditions

Plasma. Grossly hemolyzed specimens.


After separation from cells: Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: 1 year


Quantitative Chemiluminescent Immunoassay




Within 24 hours

Reference Interval

Effective February 19, 2013

0-13 days 5,000-105,000 ng/mL 5,000-105,000 ng/mL
14-30 days 300-60,000 ng/mL 300-60,000 ng/mL
1 month 100-10,000 ng/mL 100-10,000 ng/mL
2 months 40-1,000 ng/mL 40-1,000 ng/mL
3 months 11-300 ng/mL 11-300 ng/mL
4 months 5-200 ng/mL 5-200 ng/mL
5 months 0-90 ng/mL 0-90 ng/mL
6-11 months 0-90 ng/mL 0-99 ng/mL
1 year 0-19 ng/mL 0-36 ng/mL
2 years 0-12 ng/mL 0-12 ng/mL
3-6 years 0-5 ng/mL 0-5 ng/mL
7 years and older 0-9 ng/mL 0-9 ng/mL

Interpretive Data

The Beckman Coulter Access DxI AFP method is used. Results obtained with different assay methods or kits cannot be used interchangeably. AFP is a valuable aid in the management of nonseminomatous testicular cancer patients when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased AFP concentrations have also been observed in ataxia telangiectasia, hereditary tyrosinemia, primary hepatocellular carcinoma, teratocarcinoma, gastrointestinal tract cancers with and without liver metastases, and in benign hepatic conditions such as acute viral hepatitis, chronic active hepatitis, and cirrhosis. The result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. The result is not interpretable as a tumor marker in pregnant females.

Compliance Category



Adult males and nonpregnant females:  0.0-9.0 ng/mL

For CSF, refer to Alpha Fetoprotein, CSF (Tumor Marker)(ARUP test code 0020729).
For peritoneal (ascites), pleural and pericardial fluid, refer to Alpha Fetoprotein, Body Fluid (ARUP test code 2014507).

Hotline History


CPT Codes



Component Test Code* Component Chart Name LOINC
0080428 Alpha Fetoprotein Tumor Marker 53962-7
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • AFP
Alpha Fetoprotein, Serum (Tumor Marker)